Clinical significance of the time-average systemic immunoinflammatory index in primary immunoglobulin A nephropathy: a bicentric retrospective cohort study
Kidney Research and Clinical Practice · 28.10.2026 · 45 (6) · 967-977
DOI: 10.23876/j.krcp.24.260 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Kidney Research and Clinical Practice, erschienen am 28.10.2026. Verfasst von Ya Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Fuyang People's Hospital affiliated with Anhui Medical University, Fuyang, China. 497356558@qq.com. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Background
Systemic immune inflammation index (SII) is a potential marker that can reflect the systemic inflammatory response. However, the clinical significance of SII for immunoglobulin A nephropathy (IgAN) has yet to be determined.
Methods
This was a retrospective analysis, covering January 2011 to December 2023, involving 1,399 IgAN patients confirmed through renal biopsy. The low TASII (L-TASII) group comprised patients with a time-average SII (TASII) below the top third of the cohort, whereas the high TASII (H-TASII) group included all remaining patients. All patients were matched 1:1 according to age, sex, follow-up time, and baseline estimated glomerular filtration rate (eGFR). Clinical pathology and prognosis were assessed and compared between the two groups.
Results
After matching, the L-TASII and H-TASII groups each feature 556 cases. Patients in the H-TASII group had lower albumin levels (36.88 ± 6.24 g/L vs. 37.93 ± 5.45 g/L, p = 0.01) and higher proteinuria levels (2.19 ± 2.25 g/day vs. 1.75 ± 2.07 g/day, p = 0.003). With an eGFR ≥30% when compared with the baseline or end-stage renal disease as the composite endpoint events, Kaplan-Meier curve analysis revealed that after an average follow-up of 59.91 ± 32.42 months, the survival rate was markedly lower in the H-TASII group than in L-TASII group (log-rank p < 0.01). Analysis revealed that TASII levels are independent predictors for the occurrence of endpoint events (hazard ratio, 1.02; 95% confidence interval, 1.01–1.04; p = 0.001).
Conclusion
IgAN patients with a high TASII have more serious clinical manifestations such as creatinine, urinary protein, and inflammatory markers, while there is a worse prognosis for patients with low TASII. Thus, the TASII score represents a significant risk factor for adverse renal outcomes in IgAN patients and serves as a reliable predictor of renal survival.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Fuyang People's Hospital affiliated with Anhui Medical University, Fuyang, China. 497356558@qq.com.
- Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Nephrology, Fuyang People's Hospital affiliated with Anhui Medical University, Fuyang, China.
Förderung
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Hu, Y., Huang, Z., Zhao, W., Zhang, H., Li, G., Lin, S., Feng, F., Chen, C., & Liu, Z. (2026). Clinical significance of the time-average systemic immunoinflammatory index in primary immunoglobulin A nephropathy: a bicentric retrospective cohort study. Kidney Research and Clinical Practice, 45(6), 967-977. https://doi.org/10.23876/j.krcp.24.260
Vancouver
Hu Y, Huang Z, Zhao W, Zhang H, Li G, Lin S, et al. Clinical significance of the time-average systemic immunoinflammatory index in primary immunoglobulin A nephropathy: a bicentric retrospective cohort study. Kidney Research and Clinical Practice. 2026;45(6):967-977. doi:10.23876/j.krcp.24.260
BibTeX
@article{Hu2026,
author = {Hu, Ya and Huang, Ziyuan and Zhao, Wanwan and Zhang, Hong and Li, Ganxiu and Lin, Sishi and Feng, Fangfang and Chen, Chaosheng and Liu, Zewen},
title = {Clinical significance of the time-average systemic immunoinflammatory index in primary immunoglobulin A nephropathy: a bicentric retrospective cohort study},
journal = {Kidney Research and Clinical Practice},
year = {2026},
volume = {45},
number = {6},
pages = {967--977},
doi = {10.23876/j.krcp.24.260}
}
EUVIMED